ADVM vs. GNFT, CGEN, ELEV, FENC, KOD, CLLS, VCXB, IPSC, XFOR, and INMB
Should you be buying Adverum Biotechnologies stock or one of its competitors? The main competitors of Adverum Biotechnologies include Genfit (GNFT), Compugen (CGEN), Elevation Oncology (ELEV), Fennec Pharmaceuticals (FENC), Kodiak Sciences (KOD), Cellectis (CLLS), 10X Capital Venture Acquisition Corp. III (VCXB), Century Therapeutics (IPSC), X4 Pharmaceuticals (XFOR), and INmune Bio (INMB). These companies are all part of the "biological products, except diagnostic" industry.
Adverum Biotechnologies (NASDAQ:ADVM) and Genfit (NASDAQ:GNFT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, community ranking, institutional ownership, media sentiment and risk.
Adverum Biotechnologies has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Comparatively, Genfit has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500.
Genfit has higher revenue and earnings than Adverum Biotechnologies.
Adverum Biotechnologies received 300 more outperform votes than Genfit when rated by MarketBeat users. However, 68.09% of users gave Genfit an outperform vote while only 60.97% of users gave Adverum Biotechnologies an outperform vote.
In the previous week, Adverum Biotechnologies had 10 more articles in the media than Genfit. MarketBeat recorded 16 mentions for Adverum Biotechnologies and 6 mentions for Genfit. Genfit's average media sentiment score of 0.58 beat Adverum Biotechnologies' score of 0.15 indicating that Genfit is being referred to more favorably in the news media.
Adverum Biotechnologies presently has a consensus target price of $29.00, suggesting a potential upside of 231.43%. Genfit has a consensus target price of $11.00, suggesting a potential upside of 189.47%. Given Adverum Biotechnologies' higher probable upside, analysts clearly believe Adverum Biotechnologies is more favorable than Genfit.
Genfit's return on equity of 0.00% beat Adverum Biotechnologies' return on equity.
48.2% of Adverum Biotechnologies shares are owned by institutional investors. Comparatively, 2.2% of Genfit shares are owned by institutional investors. 4.2% of Adverum Biotechnologies shares are owned by company insiders. Comparatively, 4.2% of Genfit shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Genfit beats Adverum Biotechnologies on 7 of the 13 factors compared between the two stocks.
Get Adverum Biotechnologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ADVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Adverum Biotechnologies Competitors List
Related Companies and Tools
